The Democratic Co-Chairs of Congressional Cannabis Caucus try to free up the top drug adviser to President Donald Trump, allowing him to express his views on the legalization of cannabis.
Dina Titus and Ilhan Oma, both Democrats from the U.S. House of Representatives, presented on April 29, 2019 an Evidence-Based Drug Policy Act of 2020 to eliminate drugs. Restriction on the use of On the Executive Branch, related to research and policy on Schedule I controlled drugs.
This act will allow the White House Office of National Drug Control Policy, or ONDCP to fund and/or support research related to adult-use marijuana as well as medical marijuana. The act would also remove the restrictions which force the ONDCP Director to oppose legalizing Schedule I drugs before U.S. Food and Drug Administration approves them.
Titus, in a statement to the press: “The Office of National Drug Control Policy should have freedom to conduct research and speak out about substances like marijuana based on research and evidence.” Release An announcement of the new legislation. The law should not restrict what is studied or mandate that we oppose attempts to redistribute substances, such as marijuana. The law needs to be updated to reflect cannabis’ current medical use in the United States. It’s time for the federal government to catch up with states.”
Congresswomen brought the legislation to the fore after a National Academies Act 2024. Studying It was recommended that Congress permit the ONDCP study of the effects of marijuana legalization.
Omar stated that “our nation’s drug policy has been shaped by the stigma.” The American people have overwhelmingly endorsed drug policies. Support The federal government still tries to stifle the efforts of experts in the field. Evidence-Based Drug Policy Act aims to bring our laws up-to-date and ensure that the Office of National Drug Control Policy is guided by fact, rather than outdated ideologies. The drug policy must reflect current realities in the states and follow science.
The legislation, if passed, would give Sara Carter, Trump’s nominee to be the ONDCP Director, the chance to freely speak on cannabis reform. This includes a proposed Schedule III rule by Trump. His support during the election campaign in 2024.
In nominating Carter last month on Truth Social, Trump Hailed She has been a Fox News reporter since 2005, covering the fentanyl crisis and opioid epidemics.
Carter stated on her podcast that, despite a federal law prohibiting ONDCP directors to endorse cannabis legalization in November 2023, she has no problem with the idea.
She said, “I have no problem with it if it is legalized and monitored.” You can also read about the importance of this in our article. “I know I have some issues with it, but I think that using cannabis as a medicine and for medical reasons, is the best way for those who suffer from cancer or other illnesses to deal with the disease and side effects. Then I don’t think we should make it illegal.
The Evidence-Based Drug Policy Act has the support of several trade and industry associations and advocacy groups, such as the Drug Policy Alliance and the National Cannabis Industry Association. Other organizations include the Marijuana Policy Project and the U.S. Cannabis Roundtable.
Charlie Bachtell said, “The roundtable is strongly in support of the legislation that will ensure researchers can conduct rigorous research about medical cannabis and marijuana legalization.”
“The Department of Health and Human Services determined in 2023 that cannabis has low abuse potential and accepted medical use, and 80% of states allow some form of legal cannabis,” he said in the release. Our nation’s guidelines for research should reflect that reality.
The HHS has determined that cannabis is currently used for medical purposes in the U.S., and it recommended its reclassification to Schedule III. However, the final decision rests with the Drug Enforcement Administration (DEA), which reports to U.S. attorney general Pam Bondi.
The Democratic cochairs of Congressional Cannabis Caucus have been trying to open the mouth of Donald Trump’s chief drug advisor, allowing the woman to speak freely about her position on the legalization of cannabis.
Dina Titus and Ilhan Oma, both Democrats from the U.S. House of Representatives, presented on April 29, 2019 an Evidence-Based Drug Policy Act of 2020 to eliminate drugs. Restriction on the use of On the Executive Branch in relation to research and policy on Schedule I Controlled Substances.
The act allows the White House Office of National Drug Control Policy to sponsor and/or finance research on medical cannabis or adult use. It would also lift restrictions forcing the ONDCP to refuse legalizing Schedule I drugs before U.S. Food and Drug Administration approval.
Titus, in a statement to the press said: “The Office of National Drug Control Policy should have freedom to speak or sponsor research about substances like marijuana based on research evidence.” Release An announcement of the new legislation. The law should not restrict what is studied or mandate that we oppose attempts to redistribute substances, such as marijuana. The law needs to be updated to reflect cannabis’s current medical use in the United States. It’s time for the federal government to catch up with states.”
Congresswomen brought the legislation to the fore after a National Academies Act 2024. Studying The ONDCP was asked to conduct a study on the effects of legalizing cannabis.
Omar stated that “our nation’s drug policy has been shaped by the stigma.” The American people have overwhelmingly endorsed drug policies. Support The federal government still refuses to allow its experts to make any progress in cannabis reform. Evidence-Based Drug Policy Act aims to bring our laws up-to-date and ensure that the Office of National Drug Control Policy is guided by fact, rather than outdated ideologies. The drug policy must be based on scientific evidence and should reflect what is happening in the states.
The legislation, if passed, would give Sara Carter, Trump’s nominee to be the ONDCP Director, the chance to freely speak on cannabis reform. This includes a proposed Schedule III rule by Trump. His support during the election campaign in 2024.
In nominating Carter last month on Truth Social, Trump Hailed She has been a Fox News reporter since 2005, covering the fentanyl crisis and opioid epidemics.
Carter, who is the director of the ONDCP and has a prohibition on endorsing marijuana legalization under federal law, said in her podcast from November 2023 she didn’t mind it.
She said, “I have no problem with it if it is legalized and monitored.” You can also read about the importance of this in our article. “I know I have some issues with it, but I think that using cannabis as a medicine and for medical reasons, is the best way for those who suffer from cancer or other illnesses to deal with the disease and side effects. Then I don’t think we should make it illegal.
Several industry trade and advocacy associations support the Evidence-Based Drug Policy Act, including Drug Policy Alliance and the National Cannabis Industry Association. Other organizations include the Marijuana Policy Project (MPP), the U.S. Cannabis Roundtable, Minority Cannabis Business Association and NORML.
Charlie Bachtell said, “The roundtable is strongly in support of the legislation that will ensure researchers can conduct rigorous research about medical cannabis and marijuana legalization.”
“The Department of Health and Human Services determined in 2023 that cannabis has low abuse potential and accepted medical use, and 80% of states allow some form of legal cannabis,” he said in the release. Our nation’s guidelines for research should reflect that reality.
The HHS has determined that cannabis is currently used for medical purposes in the U.S., and it recommended its re-scheduling to Schedule III. However, the final decision lies with the Drug Enforcement Administration (DEA), which reports to U.S. attorney general Pam Bondi.
Cannabis Law Resources for Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. You can use these resources to learn about the requirements for certification, permissions and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland